Blanca Humanes1, Sonia Camaño1, Jose Manuel Lara2, Venkatta Sabbisetti3, María Ángeles González-Nicolás1, Joseph V Bonventre3, Alberto Tejedor1,4, Alberto Lázaro1,3. 1. Renal Physiopathology Laboratory, Department of Nephrology, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Hospital General Universitario Gregorio Marañón, Madrid, Spain. 2. Department of Pathology, IiSGM-Hospital General Universitario Gregorio Marañón, Madrid, Spain. 3. Renal Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 4. Department of Medicine, Faculty of Medicine, Universidad Complutense de Madrid, Madrid, Spain.
Abstract
BACKGROUND: Cisplatin is a potent chemotherapeutic drug whose nephrotoxic effect is a major complication and a dose-limiting factor for antitumoral therapy. There is much evidence that inflammation contributes to the pathogenesis of cisplatin-induced nephrotoxicity. We found that cilastatin, a renal dehydropeptidase-I inhibitor, has protective effects in vitro and in vivo against cisplatin-induced renal damage by inhibiting apoptosis and oxidation. Here, we investigated the potential use of cilastatin to protect against cisplatin-induced kidney injury and inflammation in rats. METHODS: Male Wistar rats were divided into four groups: control, cilastatin-control, cisplatin and cilastatin-cisplatin. Nephrotoxicity was assessed 5 days after administration of cisplatin based on blood urea nitrogen, creatinine, glomerular filtration rate (GFR), kidney injury molecule (KIM)-1 and renal morphology. Inflammation was measured using the electrophoretic mobility shift assay, immunohistochemical studies and evaluation of inflammatory mediators. RESULTS: Compared with the control rats, cisplatin-administered rats were affected by significant proximal tubule damage, decreased GFR, increased production of inflammatory mediators and elevations in urea, creatinine and tissue KIM-1 levels. Cilastatin prevented these changes in renal function and ameliorated histological damage in cisplatin-administered animals. Cilastatin also reduced pro-inflammatory cytokine levels, activation of nuclear factor-κB and CD68-positive cell concentrations. CONCLUSIONS: Cilastatin reduces cisplatin-induced nephrotoxicity, which is associated with decreased inflammation in vivo. Although the exact role of decreased inflammation in nephroprotection has not been fully elucidated, treatment with cilastatin could be a novel strategy for the prevention of cisplatin-induced acute kidney injury.
BACKGROUND: Cisplatin is a potent chemotherapeutic drug whose nephrotoxic effect is a major complication and a dose-limiting factor for antitumoral therapy. There is much evidence that inflammation contributes to the pathogenesis of cisplatin-induced nephrotoxicity. We found that cilastatin, a renal dehydropeptidase-I inhibitor, has protective effects in vitro and in vivo against cisplatin-induced renal damage by inhibiting apoptosis and oxidation. Here, we investigated the potential use of cilastatin to protect against cisplatin-induced kidney injury and inflammation in rats. METHODS: Male Wistar rats were divided into four groups: control, cilastatin-control, cisplatin and cilastatin-cisplatin. Nephrotoxicity was assessed 5 days after administration of cisplatin based on blood urea nitrogen, creatinine, glomerular filtration rate (GFR), kidney injury molecule (KIM)-1 and renal morphology. Inflammation was measured using the electrophoretic mobility shift assay, immunohistochemical studies and evaluation of inflammatory mediators. RESULTS: Compared with the control rats, cisplatin-administered rats were affected by significant proximal tubule damage, decreased GFR, increased production of inflammatory mediators and elevations in urea, creatinine and tissue KIM-1 levels. Cilastatin prevented these changes in renal function and ameliorated histological damage in cisplatin-administered animals. Cilastatin also reduced pro-inflammatory cytokine levels, activation of nuclear factor-κB and CD68-positive cell concentrations. CONCLUSIONS: Cilastatin reduces cisplatin-induced nephrotoxicity, which is associated with decreased inflammation in vivo. Although the exact role of decreased inflammation in nephroprotection has not been fully elucidated, treatment with cilastatin could be a novel strategy for the prevention of cisplatin-induced acute kidney injury.
Authors: Sonia Camano; Alberto Lazaro; Estefania Moreno-Gordaliza; Ana M Torres; Carmen de Lucas; Blanca Humanes; Jose A Lazaro; M Milagros Gomez-Gomez; Lisardo Bosca; Alberto Tejedor Journal: J Pharmacol Exp Ther Date: 2010-04-30 Impact factor: 4.030
Authors: J Deng; Y Kohda; H Chiao; Y Wang; X Hu; S M Hewitt; T Miyaji; P McLeroy; B Nibhanupudy; S Li; R A Star Journal: Kidney Int Date: 2001-12 Impact factor: 10.612
Authors: Blanca Humanes; Alberto Lazaro; Sonia Camano; Estefanía Moreno-Gordaliza; Jose A Lazaro; Montserrat Blanco-Codesido; Jose M Lara; Alberto Ortiz; Maria M Gomez-Gomez; Pablo Martín-Vasallo; Alberto Tejedor Journal: Kidney Int Date: 2012-06-20 Impact factor: 10.612
Authors: Lawrence H Lu; Dong-Jin Oh; Belda Dursun; Zhibin He; Thomas S Hoke; Sarah Faubel; Charles L Edelstein Journal: J Pharmacol Exp Ther Date: 2007-10-11 Impact factor: 4.030
Authors: Alfeu Zanotto-Filho; Subapriya Rajamanickam; Eva Loranc; V Pragathi Masamsetti; Aparna Gorthi; July Carolina Romero; Sonal Tonapi; Rosangela Mayer Gonçalves; Robert L Reddick; Raymond Benavides; John Kuhn; Yidong Chen; Alexander J R Bishop Journal: Cancer Lett Date: 2018-03-30 Impact factor: 8.679
Authors: Estefanía Moreno-Gordaliza; Diego Esteban-Fernández; Alberto Lázaro; Sarah Aboulmagd; Blanca Humanes; Alberto Tejedor; Michael W Linscheid; M Milagros Gómez-Gómez Journal: J Lipid Res Date: 2018-07-26 Impact factor: 5.922